The novel SHIP-1 activator AQX-435 was demonstrated to be effective in the inhibition of anti-IgM-induced AKT phosphorylation, resulting in CLL cell apoptosis in vitro (61). Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.